secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2022-01-03T23:59:59+00:00
Accession:  0001493152-22-000069
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma gets FDA Rare Pediatric Disease designation for IMX-110 in rhabdomyosarcoma
--------------------------------------------------------------------------------

- FDA granted Rare Pediatric Disease designation for IMX-110 to treat rhabdomyosarcoma, a life-threatening pediatric cancer.
- If approved, Immix may receive a Priority Review Voucher (PRV), historically sold for $67M to $350M, transferable to other companies.
- IMX-110 is currently in a Phase 1b/2a clinical trial and also has orphan drug designation for soft tissue sarcoma.
- Company believes IMX-110 targets all three components of the tumor micro-environment via its SMARxT platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222000069/0001493152-22-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315222000069/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer